H Wang1, K Kleiman1, J Wang1, W Luo1, C Guo1, D T Eitzman1. 1. Department of Internal Medicine, Cardiovascular Research Center, University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Proinflammatory cytokines are associated with cardiovascular diseases, including acute and recurrent myocardial infarction. However, the causal role of cytokines in thrombotic complications of atherosclerosis remains unclear. Interleukin-1β (IL-1β) is currently being targeted in a human clinical trial for the prevention of ischemic events. OBJECTIVES: The purpose of the present study was to test the role of IL-1β in arterial thrombosis and a potential protective effect of P-selectin glycoprotein ligand-1 (Psgl-1) deficiency. METHODS AND RESULTS: Wild-type and Psgl-1-deficient mice were treated with IL-1β and then subjected to carotid photochemical injury to induce thrombosis. IL-1β shortened the time to thrombosis in wild-type mice, while Psgl-1(-/-) mice were protected from the prothrombotic effects of IL-1β. A neutralizing antibody to Psgl-1 was also effective in protecting against the prothrombotic effects of IL-1β. The protective effect of Psgl-1 deficiency was associated with reduced plasma levels of soluble P-selectin and collagen-stimulated whole blood aggregation. CONCLUSIONS: Our data demonstrate that Psgl-1 deficiency is protective against the prothrombotic effects of IL-1β and suggest that Psgl-1 inhibition may be a useful treatment strategy for targeting vascular thrombosis associated with enhanced inflammatory states.
BACKGROUND: Proinflammatory cytokines are associated with cardiovascular diseases, including acute and recurrent myocardial infarction. However, the causal role of cytokines in thrombotic complications of atherosclerosis remains unclear. Interleukin-1β (IL-1β) is currently being targeted in a human clinical trial for the prevention of ischemic events. OBJECTIVES: The purpose of the present study was to test the role of IL-1β in arterial thrombosis and a potential protective effect of P-selectin glycoprotein ligand-1 (Psgl-1) deficiency. METHODS AND RESULTS: Wild-type and Psgl-1-deficient mice were treated with IL-1β and then subjected to carotid photochemical injury to induce thrombosis. IL-1β shortened the time to thrombosis in wild-type mice, while Psgl-1(-/-) mice were protected from the prothrombotic effects of IL-1β. A neutralizing antibody to Psgl-1 was also effective in protecting against the prothrombotic effects of IL-1β. The protective effect of Psgl-1 deficiency was associated with reduced plasma levels of soluble P-selectin and collagen-stimulated whole blood aggregation. CONCLUSIONS: Our data demonstrate that Psgl-1 deficiency is protective against the prothrombotic effects of IL-1β and suggest that Psgl-1 inhibition may be a useful treatment strategy for targeting vascular thrombosis associated with enhanced inflammatory states.
Authors: Lea M Beaulieu; Elaine Lin; Eric Mick; Milka Koupenova; Ellen O Weinberg; Carolyn D Kramer; Caroline A Genco; Kahraman Tanriverdi; Martin G Larson; Emelia J Benjamin; Jane E Freedman Journal: Arterioscler Thromb Vasc Biol Date: 2014-01-23 Impact factor: 8.311
Authors: Hana M Russo; Kevin J Wickenheiser; Wei Luo; Miina K Ohman; Luigi Franchi; Andrew P Wright; Peter F Bodary; Gabriel Núñez; Núñez Gabriel; Daniel T Eitzman Journal: Circ Res Date: 2010-06-17 Impact factor: 17.367
Authors: Paula da Costa Martins; Juan-Jesús García-Vallejo; Johannes V van Thienen; Mar Fernandez-Borja; Janine M van Gils; Cora Beckers; Anton J Horrevoets; Peter L Hordijk; Jaap-Jan Zwaginga Journal: Arterioscler Thromb Vasc Biol Date: 2007-02-22 Impact factor: 8.311
Authors: Hui Wang; Wei Luo; Jintao Wang; Chiao Guo; Stephanie L Wolffe; Julia Wang; Eddy B Sun; Kori N Bradley; Andrew D Campbell; Daniel T Eitzman Journal: Br J Haematol Date: 2013-04-17 Impact factor: 6.998
Authors: Paul M Ridker; Campbell P Howard; Verena Walter; Brendan Everett; Peter Libby; Johannes Hensen; Tom Thuren Journal: Circulation Date: 2012-11-05 Impact factor: 29.690
Authors: J Yang; T Hirata; K Croce; G Merrill-Skoloff; B Tchernychev; E Williams; R Flaumenhaft; B C Furie; B Furie Journal: J Exp Med Date: 1999-12-20 Impact factor: 14.307